Stroke, Vol 23, 1400-1403, Copyright © 1992 by American Heart Association
H Tohgi, S Konno, K Tamura, B Kimura and K Kawano
BACKGROUND AND PURPOSE: The purpose of this study was to compare the
effects of low-to-high doses of aspirin on platelet aggregability
determined by different methods and on the metabolism of thromboxane A2 and
prostacyclin. METHODS: We administered increasing doses (40, 320, and 1,280
mg/day) of aspirin to 19 poststroke patients and studied the differences in
1) the changes in platelet aggregability depending on the methods of
evaluation and 2) the concentrations of prostaglandin metabolites in the
blood and urine. RESULTS: Aggregation of platelet- rich plasma induced by a
strong stimulus (10 microM ADP) was significantly reduced after 40 mg/day
aspirin (p less than 0.005), and this reduction was similar to that after
higher aspirin doses. In contrast, aggregation of platelet-rich plasma
induced by weaker stimuli (1 and 5 microM ADP) decreased less significantly
after 40 mg/day aspirin compared with that after higher aspirin doses. The
serum thromboxane B2 generated after ex vivo incubation was reduced
significantly (by 85%) after 40 mg/day aspirin and decreased further after
320 mg/day (by 96%) and 1,280 mg/day (by greater than 99%) of aspirin. The
urinary 11-dehydro-thromboxane B2 concentration decreased less
significantly after 40 mg/day aspirin (by 42%) compared with that after 320
mg/day (by 78%) and 1,280 mg/day (by 91%) aspirin doses. The urinary
concentration of 2,3-dinor-6-keto-prostaglandin F1 alpha did not decrease
after 40 mg/day aspirin but decreased significantly after higher doses of
aspirin. CONCLUSIONS: These findings suggest that different doses of
aspirin may be necessary to prevent thrombogenesis induced by different
triggers of different strengths and that 40 mg/day aspirin is able to
inhibit a large proportion of maximum thromboxane A2 release provoked
acutely, with the prostaglandin I2 synthesis being little affected;
however, higher doses of aspirin are required to attain further inhibition.
ARTICLES
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin
Department of Neurology, Iwate Medical University, Morioka, Japan.
This article has been cited by other articles:
 |
|
 |
|
  M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D. A. Palisaitis, and J. G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur. Heart J., July 2, 2007; 28(14): 1702 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bruno, J. P. McConnell, S. N. Cohen, G. E. Tietjen, R. A. Wallis, P. B. Gorelick, and N. U. Bang Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction Stroke, March 1, 2004; 35(3): 727 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tanaka, H. Tanaka, and S. Abe High Dose of Inhaled Fluticasone Reduces High Levels of Urinary Leukotriene E4 in the Early Morning in Mild and Moderate Nocturnal Asthma Chest, November 1, 2003; 124(5): 1768 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Dorhout Mees, G. J.E. Rinkel, J. W. Hop, A. Algra, and J. van Gijn Antiplatelet Therapy in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review Stroke, September 1, 2003; 34(9): 2285 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guazzi, R. Brambilla, G. Reina, G. Tumminello, and M. D. Guazzi Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure: A Dose-Related Adverse Effect of Aspirin Arch Intern Med, July 14, 2003; 163(13): 1574 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Eikelboom and G. J. Hankey Aspirin resistance:a new independent predictor of vascular events? J. Am. Coll. Cardiol., March 19, 2003; 41(6): 966 - 968. [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, J. P. McConnell, H. H. Mansbach, III, S. N. Cohen, G. E. Tietjen, and N. U. Bang Aspirin and Urinary 11-Dehydrothromboxane B2 in African American Stroke Patients Stroke, January 1, 2002; 33(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kurokawa, H. Tanaka, S. Tanaka, and S. Abe Circadian Characteristics of Urinary Leukotriene E4 in Healthy Subjects and Nocturnal Asthmatic Patients Chest, December 1, 2001; 120(6): 1822 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Gum, M. Thamilarasan, J. Watanabe, E. H. Blackstone, and M. S. Lauer Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease: A Propensity Analysis JAMA, September 12, 2001; 286(10): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Hop, G. J. E. Rinkel, A. Algra, J. W. B. van der Sprenkel, and J. van Gijn Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage Neurology, February 22, 2000; 54(4): 872 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Igawa, R. Kornhauser, D. D. Cilla, J. O'Neal King, and J. Kambayashi State-of-the-Art Review : Evaluation of the Clot Signature Analyzer as a Hemostasis Test in Healthy Volunteers Exposed to Low Doses of Aspirin Clinical and Applied Thrombosis/Hemostasis, April 1, 1999; 5(2): 117 - 121. [Abstract] [PDF]
|
|
|
|
|
|
J. Valles, M. T. Santos, J. Aznar, A. Osa, A. Lago, J. Cosin, E. Sanchez, M. J. Broekman, and A. J. Marcus Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality : The Effect of Low-Dose Aspirin Is Less Than Optimal in Patients With Vascular Disease Due to Prothrombotic Effects of Erythrocytes on Platelet Reactivity Circulation, February 3, 1998; 97(4): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishimura, H. Naritomi, Y. Iwamoto, H. Tachibana, and M. Sugita In Vivo Evaluation of Antiplatelet Agents in Gerbil Model of Carotid Artery Thrombosis Stroke, June 1, 1996; 27(6): 1099 - 1104. [Abstract] [Full Text]
|
|
|
|
|
|
R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text]
|
|
|
|
|
|
J. H. Vial and C. Narkowicz Comparison of Cyclooxygenase Inhibition with Two Different Doses of Enteric Coated Aspirin in Normal Young and Elderly Subjects and Elderly with Cerebrovascular Disease Clinical and Applied Thrombosis/Hemostasis, January 1, 1995; 1(1): 55 - 61. [Abstract] [PDF]
|
|